Lindbrook Capital LLC Sells 113 Shares of Novartis AG (NYSE:NVS)

Lindbrook Capital LLC cut its position in shares of Novartis AG (NYSE:NVS) by 2.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,816 shares of the company’s stock after selling 113 shares during the quarter. Lindbrook Capital LLC’s holdings in Novartis were worth $371,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Foundations Investment Advisors LLC grew its holdings in Novartis by 26.9% during the 4th quarter. Foundations Investment Advisors LLC now owns 89,074 shares of the company’s stock worth $8,668,000 after acquiring an additional 18,894 shares during the period. CWA Asset Management Group LLC grew its stake in Novartis by 20.1% during the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company’s stock worth $3,001,000 after purchasing an additional 5,164 shares during the period. Quantbot Technologies LP increased its holdings in Novartis by 135.5% in the third quarter. Quantbot Technologies LP now owns 39,976 shares of the company’s stock worth $4,598,000 after purchasing an additional 22,998 shares in the last quarter. Chicago Partners Investment Group LLC bought a new stake in Novartis in the fourth quarter worth approximately $239,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Novartis by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 157,256 shares of the company’s stock valued at $18,088,000 after buying an additional 18,990 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis Stock Performance

Shares of Novartis stock opened at $113.00 on Friday. Novartis AG has a 52 week low of $92.35 and a 52 week high of $120.92. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The business has a 50 day moving average price of $103.67 and a 200-day moving average price of $108.02. The company has a market cap of $230.97 billion, a PE ratio of 19.22, a price-to-earnings-growth ratio of 1.70 and a beta of 0.53.

Novartis (NYSE:NVS) last released its quarterly earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Equities analysts anticipate that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. StockNews.com upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 8th. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a research note on Thursday, February 13th. HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Barclays reaffirmed an “underweight” rating on shares of Novartis in a research report on Monday, February 3rd. Finally, Morgan Stanley initiated coverage on Novartis in a report on Wednesday, February 12th. They issued an “underweight” rating on the stock. Three analysts have rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.